## 3 Results and Discussion
### The Top-Ranked Molecules from the Traditional Concections  
The results of the analysis of the seven docking scores and five consensus methods show that the two potential inhibitors of FLAT3, from the traditional concoction are 24815245 (rescinnamine) and 101757 (benzenamine, N-phenyl-4-(phenylazo)). The two most prominent inhibitors of BCL-2 are 865043 (methoserpidine) and 603509 (bisacodyl), while that of the mutated BCL-2 G101V are 865043, and 24815245, which are already found to be the best inhibitors of BCL-2 and FLAT3, respectively. The two molecules methoserpidine (865043) and rescinnamine (24815245) that are found to be the most promising potential inhibitor of the mutated BCL-2 G101V, are very similar in structure with just a minor difference (Figure 5), but they are significantly different in function and toxicity, as explained below. The structures of these four molecules are shown in Figure 5. These molecules have been considered for biological applications, especially rescinnamine (that  
Figure 4: The binding site orientation of **(a)** gilteritinib to FLAT3 and **(b)** ventoclax to BCL-2 obtained from Molegro (green), Vina (cyan), Glide (magenta), Haddock(rigid) (yellow), Haddock(flex) (blue), and Haddock(flex, water) (red), in relation to their crystal structure crystal (orange).  
targets FLAT3 and BCL-2 G101V in this study) and bisacodyl (that targets BCL-2 in this study) are known drugs in clinical applications. Rescinnamine is a vinca alkaloid that is derived from _Rauvolfia serpentina_ and is used as an antihypertensive drug [32; 33]. Bisacodyl is a stimulant laxative drug that is being used to treat constipation and found to be both safe and effective for long-term use [34; 35]. Benzenamine, N-phenyl-4-(phenylazo), which can also be called benzeneacdiphenylamine, is part of the diphenylamine derivatives that are well known to act as an antioxidant, but not considered seriously for use in edible products for the fear of toxicity [36]. Methoserpidine is a synthetic isomer of reserpine that is being used as an antihypertensive drug but found to have a side effect that results in mental depression [37; 38].  
The binding site residues interactions of rescinnamine with FLAT3 and the mutated BCL-2 G101V, and the interaction of bisacodyl with BCL-2 are shown in Figure 6 in an effort to compare their residue interactions with the residue interactions that defined the activity of the gilteritnib interaction with FLAT3 and the ventoclax interaction with BCL-2 and the mutated BCL-2 G101V, using their crystal interaction structures. The crystal interaction of ventoclax with BCL-2 and the mutated BCL-2 G101V are very similar in terms of protein residue interaction with only a minor difference that involves the Arg146 interaction in BCL-2, but Phe 153 interaction in the mutated BCL-2 G101V. The interaction of bisacodyl occupies some of the binding pockets that defined the activity of ventoclax, in its interaction with BCL-2, as they both share many residue interactions in common, such as Phe 104, Arg146, Tyr 108, Leu 137, Glue 136, Met 115, and Asp 111. The interaction of rescinnamine with the mutated BCL-2 G101V is also very similar to what was observed for the interaction of bisacodyl with BCL-2. The rescinnamine interaction with the mutated BCL-2 G101V was found to occupy a greater portion of the binding pockets that define the activity of ventoclax, as they shared many common residue interactions, such as Tyr 202, Val 148, Ala 100, Tyr 108, Phe 104, Asp 111, and Leu 137. The rescinnamine interaction with FLAT3 also shared some similar residue interactions that define the activity  
Figure 5: The known antileukemia drugs ventoclax and gliteritinib that target BCL-2 and FLAT3, respectively, and the four most promising antileukemia candidates predicted from the docking study.  
of the gilteritinib interaction with FLAT3, such as residues Cys 695, Gly 697, Lys 614, and Asp 698.